Navigation Links
Isis and Partners Present New Research at the American Association for Cancer Research 2009 Annual Meeting
Date:4/20/2009

antisense technology and adds to our previously published work using antisense to target different classes of RNAs, including microRNAs and other non-coding RNAs. We and our collaborators have shown that antisense inhibition of non-coding RNAs can impact splicing patterns in cells to modulate the expression of multiple proteins that may be involved in disease," said C. Frank Bennett, Ph.D., Senior Vice President of Research at Isis Pharmaceuticals. "Furthermore, the work of our team on STAT5 provides yet another oncology target with the potential for anti-tumor activity. We believe that antisense drugs have pharmaceutical properties that make them attractive therapeutics for cancer, and we are expanding our efforts in cancer to include new targets and new approaches."

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding Isis' business, its drug discovery an
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Brazils top automakers to distribute 2 million copies of the Ethanol Handbook in partnership with the Brazilian Sugarcane Industry Association
2. Childrens Memorial Research Center, Chicago Becomes a Member of GeneGos MetaMiner Stem Cell Partnership Program
3. ViewRay Incorporated Closes $15M Tranche of Series B Financing and Announces Partnership with Siemens AG
4. US Oncology Clinical Development Attends Partnerships With CROs
5. Aviation partners to cut 500,000 tonnes of CO2 a year
6. ChemImage and Next Breath Structure Partnership to Validate Bioequivalence Testing for Nasal Spray Suspensions
7. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
8. Van Andel Institute Joins the MetaMiner Oncology Partnership Program
9. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
10. Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
11. The NIHR Biomedical Research Centre for Mental Health London has Joined the MetaMiner CNS Partnership Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  A novel ... to help physicians better identify early-stage disease, when ... disability, according to a new study in The ... Diagnostics (NYSE: DGX ) and other ... 14-3-3eta protein outperformed conventional antibody-serum testing, including rheumatoid ...
(Date:8/27/2014)... “We are honored to be named to this ... of Radiant Sage. “We are offering truly ground-breaking clinical ... market to a different level. We are enabling ... and effectively manage the massive amounts of medical imaging ... read by trained physicians. Being recognized by technology industry ...
(Date:8/27/2014)... Aug. 27, 2014 Guggenheim Securities, the investment ... announced the hiring of veteran equity analyst Charles "Tony" ... Mr. Butler will focus on the biotech/biopharma sector. ... wealth of experience and a broad network of relationships ... Managing Director and Head of Equities at Guggenheim Securities. ...
(Date:8/27/2014)... 2014 Reportbuyer.com has added a new ... - A Rational View https://www.reportbuyer.com/product/1595336/The-Graphene-Opportunity---A-Rational-View.html ... A similar amount of hype currently surrounds ... microelectronics to water treatment, but is graphene the ... the Graphene Opportunity Report, authored by Tim ...
Breaking Biology Technology:Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced that the ... 28, 2010 , after the market closes. The press release will be followed ... open to the public via telephone and webcast. During the conference call, the ... , , ...
... EXTON, Pa. , July 21 ViroPharma Incorporated,s (Nasdaq: VPHM ... Wednesday, July 28, 2010 before the open of the U.S. financial markets. , ... The company will host a conference call and live ... the conference call, ViroPharma management will discuss the 2010 second quarter financial results and ...
... RESEARCH TRIANGLE PARK, N.C. , July 21 Chimerix, ... it has expanded its clinical management team with the appointment of ... and Herve Mommeja-Marin, MD, as Vice President of Clinical Research.   ... In these ...
Cached Biology Technology:Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast 2ViroPharma to Release 2010 Second Quarter Financial Results on July 28, 2010 2Chimerix Appoints Two New Vice Presidents to Clinical Management Team 2Chimerix Appoints Two New Vice Presidents to Clinical Management Team 3
(Date:8/27/2014)... CHICAGO , Aug. 27, 2014 /PRNewswire-iReach/ -- The ... hosting the 36 th Annual International Conference (EMBC,14), ... and Towers in Chicago, Illinois , ... than 2,500 global leaders, students, and industry professionals in ... Logo - http://photos.prnewswire.com/prnh/20140827/140333 ...
(Date:8/27/2014)... But every creature is a baby once. , A ... 24 very young dinosaurs and one older individual is ... caretaker, according to a new study by University of ... Dodson led the work, collaborating with researchers from China,s ... held. Hedrick is a doctoral student in the School ...
(Date:8/27/2014)... is available in German . ... the most common inherited disease affecting the peripheral nervous ... Max Planck Institute of Experimental Medicine and University Medical ... cells is impaired in rats with the disease. These ... known as myelin, which facilitates the rapid transfer of ...
Breaking Biology News(10 mins):Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3Potential therapy for incurable Charcot-Marie-Tooth disease 2
... canary in the coal mine, penguins are sounding ... world,s oceans, and the culprit isn,t only climate ... Oil pollution, depletion of fisheries and rampant ... penguin species, along with Earth,s warming climate, are ...
... current standard practice of giving infants and children 100 ... deprivation may actually inflict additional harm, researchers at UT ... by oxygen deprivation, known as hypoxic-ischemic brain injury, is ... long-term neurological damage among infants and children. This can ...
... Twelve investigators have received grants totaling $5 million ... of food allergy, a significant public health concern. ... is funded by the National Institute of Allergy ... Institutes of Health, and two advocacy groups, the ...
Cached Biology News:Penguins setting off sirens over health of world's oceans 2Penguins setting off sirens over health of world's oceans 3Penguins setting off sirens over health of world's oceans 4Resuscitation technique after brain injury may do more harm than good 2NIAID announces grants to stimulate food allergy research 2NIAID announces grants to stimulate food allergy research 3
... a commonly used technique for studying protein ... electrophoresed on SDS-PAGE and transferred to a ... they are probed with specific antibodies. Unlike ... of Southern and Northern blots, it has ...
... Basic Package Superior Protein Detection and ... ProXPRESS 2D Proteomic Imaging System is a ... proteomic and general life science research applications. ... use of all dyes in the UV ...
... our Regulatory Edition of Molecular Imaging (MI) ... for life science research and drug discovery ... with U.S. Food and Drug Administrations Code ... Electronic Records; Electronic Signatures [21 CFR Part ...
... Neutralizing synthetic peptide for OPA1-01009, OPEP-01009 is a 16 amino ... human DNA fragmentation factor (DFF). The sequence of this ... P - K - S - V - K - ... S - P - R - K(18). This ...
Biology Products: